Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › Natera Receives LCD From Palmetto for Signatera MRD Test in Colorectal Cancer Patients

Natera Receives LCD From Palmetto for Signatera MRD Test in Colorectal Cancer Patients

Sep 03, 2020
|
staff reporter

NEW YORK – Medicare Administrative Contractor Palmetto GBA released a final local coverage determination for ctDNA tests detecting minimal residual disease in patients with Stage II to Stage III colon cancer, focusing specifically on Natera's Signatera test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Regulatory News & FDA Approvals

  1. Roche SARS-CoV-2 Lateral Flow Antigen Test Could Meet Significant Demand

    Premium

  2. BGI Genomics Gets CE Mark for Multiplexed SARS-CoV-2, Influenza Tests

  3. Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

  4. FDA Grants Emergency Use Authorization for Jiangsu Well Biotech Coronavirus Antibody Test

  5. FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.